Moderna (MRNA) Net Cash Flow (2018 - 2026)

Moderna (MRNA) has 9 years of Net Cash Flow data on file, last reported at -$689.0 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 127.39% year-over-year to -$689.0 million in Q1 2026; TTM through Mar 2026 was $280.0 million, a 162.92% increase from a year earlier, with the FY2025 full-year figure at $666.0 million, up 166.67% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$689.0 million, down from $1.5 billion in the prior quarter.
• Over the last five years, Net Cash Flow for MRNA reached as high as $1.5 billion in Q4 2025 and fell as low as -$2.2 billion in Q2 2022.
• Historically, Net Cash Flow has averaged -$291.4 million across 5 years, with a median of -$148.0 million in 2025.
• Across the five-year window, Net Cash Flow plunged 1450.93% in 2022 and jumped 1232.0% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $176.0 million in 2022, then slumped by 114.2% to -$25.0 million in 2023, then soared by 1232.0% to $283.0 million in 2024, then jumped by 416.96% to $1.5 billion in 2025, then plunged by 147.1% to -$689.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$689.0 million in Q1 2026, $1.5 billion in Q4 2025, and -$148.0 million in Q3 2025.